Sun Pharmaceutical Industries Limited — Investor Meet, 06-08-2026: Analysts/Institutional Investor Meet/Con. Call Updates

Sun Pharma's Q1 FY27 saw 10.1% YoY sales growth to 15,183.6 Cr, with EBITDA up 2.7% at 4,417.7 Cr. Gross margins improved to 80.5% driven by product mix. India formulations were a highlight, growing 16% to 5,474.9 Cr, securing Sun's #1 market position with 8.5% share, fueled by strong volumes and new launches.

Global innovative medicine sales rose 12.8% to $351 million, driven by products like ILUMYA and new launches Leqselvi & Unloxcyt, which are showing good prescriber and formulary traction in the US. However, the US generic business saw a 9.7% decline to $427 million, largely due to Lenalidomide erosion and increased competition. Emerging markets grew 4.2% to $311 million amidst macro challenges.

The Organon acquisition is progressing towards a Q4 FY27 close. Sun Pharma is expanding its generic semaglutide presence globally. Management maintains a high single-digit revenue growth outlook for FY27, backed by a strong $3.4 billion net cash position and ongoing R&D investment.